Osprey Private Wealth LLC Buys 2,255 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Osprey Private Wealth LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,635 shares of the medical research company’s stock after purchasing an additional 2,255 shares during the quarter. Thermo Fisher Scientific accounts for approximately 3.4% of Osprey Private Wealth LLC’s investment portfolio, making the stock its 10th biggest position. Osprey Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $5,790,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TMO. Cypress Advisory Group LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $253,000. Intact Investment Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 34.0% in the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after acquiring an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $1,121,000. W.H. Cornerstone Investments Inc. raised its position in Thermo Fisher Scientific by 25.1% during the 4th quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company’s stock worth $1,493,000 after purchasing an additional 576 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in Thermo Fisher Scientific by 19.7% during the 4th quarter. Van ECK Associates Corp now owns 418,365 shares of the medical research company’s stock worth $217,646,000 after purchasing an additional 68,927 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $414.85 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The stock’s 50 day moving average price is $417.11 and its 200-day moving average price is $493.15. The company has a market capitalization of $156.60 billion, a PE ratio of 25.10, a PEG ratio of 2.99 and a beta of 0.78. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 EPS. The company’s revenue was up .2% compared to the same quarter last year. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TMO. UBS Group lowered their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Royal Bank of Canada lowered their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, Barclays lowered their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.